Nervous System and Brain Disorders

Prof. Dani Offen

Translational neuroscience

Prof Offen’s work has concentrated on the processes of cell death in neurodegenerative diseases, specifically in Parkinson's and ALS . He focuses on developing cell-based and genebased therapies for neurodegenerative diseases His team uses advanced methods, such as CRISPR/Cas 9 , for in vivo gene modification, and takes advantage of multiple platforms for the delivery of therapeutics into the CNS, including mesenchymal stem cells, exosomes and peptides .

Prof. Offen , PhD, is a member of the Department of Human Molecular Genetics & Biochemistry in the School of Medicine. He studied molecular biology, specializing in RNA processing, at the Weizmann Institute of Science, Israel. He furthered his education at the Albert Einstein College of Medicine, NY, USA, as a Post Doctoral Fellow, where he developed transgenic models of autoimmunity. Offen heads the Laboratory for Neurosciences at the Felsenstein Medical Research Center, Tel Aviv University. Prof. Offen is a co -founder of several biotechnology companies developing gene and cell therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics , showed efficacy in ALS patients in a Phase III clinical trial.

https://www.danioffenlab.com /

Using cell cultures and animal models, his team evaluates the effect of gene modification on cognition and behaviour, as well as on diseaserelated biochemical and histological features Recently, Prof Offen and his group conducted pioneering work in the role of stem cells in health and disease